DK3233903T3 - Kimære antigenreceptorer og anvendelsesfremgangsmåder - Google Patents
Kimære antigenreceptorer og anvendelsesfremgangsmåder Download PDFInfo
- Publication number
- DK3233903T3 DK3233903T3 DK15817277.5T DK15817277T DK3233903T3 DK 3233903 T3 DK3233903 T3 DK 3233903T3 DK 15817277 T DK15817277 T DK 15817277T DK 3233903 T3 DK3233903 T3 DK 3233903T3
- Authority
- DK
- Denmark
- Prior art keywords
- chimary
- antigen receptors
- use procedures
- procedures
- receptors
- Prior art date
Links
- 102000006306 Antigen Receptors Human genes 0.000 title 1
- 108010083359 Antigen Receptors Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14199148 | 2014-12-19 | ||
PCT/EP2015/080576 WO2016097334A1 (en) | 2014-12-19 | 2015-12-18 | Chimeric antigen receptors and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3233903T3 true DK3233903T3 (da) | 2021-02-22 |
Family
ID=52292645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15817277.5T DK3233903T3 (da) | 2014-12-19 | 2015-12-18 | Kimære antigenreceptorer og anvendelsesfremgangsmåder |
Country Status (10)
Country | Link |
---|---|
US (3) | US10865408B2 (da) |
EP (2) | EP3233903B1 (da) |
JP (1) | JP6718450B2 (da) |
CN (1) | CN107995926B (da) |
AU (1) | AU2015366305B2 (da) |
CA (2) | CA3207135A1 (da) |
DK (1) | DK3233903T3 (da) |
ES (2) | ES2999411T3 (da) |
IL (1) | IL252604B (da) |
WO (1) | WO2016097334A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
EP3065771B1 (en) | 2013-11-04 | 2019-03-20 | UTI Limited Partnership | Methods and compositions for sustained immunotherapy |
EP3233903B1 (en) | 2014-12-19 | 2020-12-09 | ETH Zürich | Chimeric antigen receptors and methods of use |
JP6920211B2 (ja) | 2015-05-06 | 2021-08-18 | ユーティーアイ リミテッド パートナーシップ | 持続療法用のナノ粒子組成物 |
WO2017004252A1 (en) * | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
KR20200004807A (ko) * | 2017-04-07 | 2020-01-14 | 유티아이 리미티드 파트너쉽 | 나노의약에서 수용체-리간드 상호작용의 효능을 측정하기 위한 어세이 |
EP3679065A4 (en) | 2017-09-06 | 2021-05-19 | California Institute of Technology | BIFUNCTIONAL SIGNALING AND RECEPTORS PRESENTING ANTIGENS (SABR) |
EP3775903A1 (en) * | 2018-04-12 | 2021-02-17 | ETH Zurich | Mammalian mhc peptide display as an epitope selection tool for vaccine design |
GB2591384B (en) * | 2018-08-14 | 2023-07-26 | Univ Texas | Single molecule sequencing peptides bound to the major histocompatibility complex |
EA202191083A1 (ru) * | 2018-10-19 | 2021-07-23 | Етх Цюрих | Химерные молекулы |
CN111676195A (zh) * | 2019-03-11 | 2020-09-18 | 北京卡替医疗技术有限公司 | 一种治疗t细胞肿瘤的ucar免疫细胞 |
WO2024026452A1 (en) | 2022-07-29 | 2024-02-01 | Repertoire Immune Medicines, Inc. | T cell epitopes associated with type 1 diabetes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004501364A (ja) * | 2000-05-25 | 2004-01-15 | スノル・モレキュラー・コーポレーション | T−細胞レセプター相互作用のモジュレーション |
US20080286312A1 (en) * | 2002-06-12 | 2008-11-20 | Gavish-Galilee Bio Applications Ltd. | Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes |
BR122020026648B1 (pt) * | 2010-09-20 | 2021-12-07 | Biontech Cell & Gene Therapies Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
EP3636664A1 (en) * | 2012-07-27 | 2020-04-15 | The Board of Trustees of the University of Illinois | Engineering t-cell receptors |
LT2956175T (lt) * | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimerinis antigeno receptorius ir jo panaudojimo būdai |
EP3233903B1 (en) | 2014-12-19 | 2020-12-09 | ETH Zürich | Chimeric antigen receptors and methods of use |
-
2015
- 2015-12-18 EP EP15817277.5A patent/EP3233903B1/en active Active
- 2015-12-18 EP EP20212399.8A patent/EP3851450B1/en active Active
- 2015-12-18 JP JP2017531730A patent/JP6718450B2/ja active Active
- 2015-12-18 DK DK15817277.5T patent/DK3233903T3/da active
- 2015-12-18 AU AU2015366305A patent/AU2015366305B2/en active Active
- 2015-12-18 CA CA3207135A patent/CA3207135A1/en active Pending
- 2015-12-18 WO PCT/EP2015/080576 patent/WO2016097334A1/en active Application Filing
- 2015-12-18 ES ES20212399T patent/ES2999411T3/es active Active
- 2015-12-18 US US15/537,418 patent/US10865408B2/en active Active
- 2015-12-18 CN CN201580068761.3A patent/CN107995926B/zh active Active
- 2015-12-18 ES ES15817277T patent/ES2857052T3/es active Active
- 2015-12-18 CA CA2969056A patent/CA2969056C/en active Active
-
2017
- 2017-06-01 IL IL252604A patent/IL252604B/en active IP Right Grant
-
2020
- 2020-11-13 US US17/098,226 patent/US11939572B2/en active Active
-
2024
- 2024-02-09 US US18/437,678 patent/US20240425847A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190345485A1 (en) | 2019-11-14 |
EP3233903B1 (en) | 2020-12-09 |
EP3233903A1 (en) | 2017-10-25 |
IL252604A0 (en) | 2017-07-31 |
CA3207135A1 (en) | 2016-06-23 |
JP2017537642A (ja) | 2017-12-21 |
ES2999411T3 (en) | 2025-02-25 |
US10865408B2 (en) | 2020-12-15 |
US20240425847A1 (en) | 2024-12-26 |
JP6718450B2 (ja) | 2020-07-08 |
AU2015366305A1 (en) | 2017-07-27 |
US11939572B2 (en) | 2024-03-26 |
EP3851450A1 (en) | 2021-07-21 |
CA2969056A1 (en) | 2016-06-23 |
EP3851450B1 (en) | 2024-11-27 |
WO2016097334A1 (en) | 2016-06-23 |
CN107995926B (zh) | 2021-07-06 |
AU2015366305B2 (en) | 2020-03-05 |
IL252604B (en) | 2021-02-28 |
CN107995926A (zh) | 2018-05-04 |
US20210123042A1 (en) | 2021-04-29 |
EP3851450C0 (en) | 2024-11-27 |
CA2969056C (en) | 2023-09-05 |
ES2857052T3 (es) | 2021-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251970B (en) | Anti-cd79b antibodies and methods of use | |
DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
DK3514172T3 (da) | Claudin-6-specifikke immunoreceptorer og t-celleepitoper | |
DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
DK3169703T3 (da) | Kimær antigenreceptor og anvendelse deraf | |
DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3212255T3 (da) | Selvorienterende sprøjte og sprøjtegrænseflade | |
DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
DK3149042T3 (da) | PD-L1-antistoffer og anvendelser deraf | |
DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
DK3227342T4 (da) | Proteinøs heterodimer og anvendelse deraf | |
DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
DK3309174T3 (da) | ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf | |
HK1255312A1 (zh) | 抗原受體及其用途 | |
DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3233903T3 (da) | Kimære antigenreceptorer og anvendelsesfremgangsmåder | |
DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
IL263627A (en) | Chimeric antigen receptors (cars) specific for muc1 and methods for their use | |
DK3117777T3 (da) | Spredningstomografifremgangsmåde og spredningstomografianordning | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3233105T3 (da) | Hidtil ukendt kombination og anvendelse | |
DK3110447T3 (da) | Anti-EGFR-antistof og anvendelser heraf |